TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancer.
作者信息
Costa D B
机构信息
Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA.
出版信息
Ann Oncol. 2018 Oct 1;29(10):2028-2030. doi: 10.1093/annonc/mdy339.
Abstract
摘要
相似文献
1
TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancer.在肺癌中，当TP53突变与ALK重排同时出现时，具有预测和预后价值。
Ann Oncol. 2018 Oct 1;29(10):2028-2030. doi: 10.1093/annonc/mdy339.
2
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.TP53 突变状态对 ALK 重排非小细胞肺癌系统治疗结局的影响。
Ann Oncol. 2018 Oct 1;29(10):2068-2075. doi: 10.1093/annonc/mdy333.
3
Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).TP53共突变对表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）患者的预后和预测作用。
Lung Cancer. 2017 Sep;111:23-29. doi: 10.1016/j.lungcan.2017.06.014. Epub 2017 Jun 24.
4
ALK fusion and its association with other driver gene mutations in Finnish non-small cell lung cancer patients.芬兰非小细胞肺癌患者中ALK融合及其与其他驱动基因突变的关联。
Genes Chromosomes Cancer. 2014 Nov;53(11):895-901. doi: 10.1002/gcc.22198. Epub 2014 Jun 19.
5
The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.ALK重排以及KRAS和EGFR突变在原发性肺黏液腺癌中的临床病理意义
Tumour Biol. 2015 Aug;36(8):6417-24. doi: 10.1007/s13277-015-3331-4. Epub 2015 Mar 28.
6
Identification of a highly lethal V3 TP53 subset in ALK lung adenocarcinoma.鉴定出 ALK 肺腺癌中高度致死的 V3 TP53 亚群。
Int J Cancer. 2019 Jan 1;144(1):190-199. doi: 10.1002/ijc.31893. Epub 2018 Oct 30.
7
Comprehensive profiling and quantitation of oncogenic mutations in non small-cell lung carcinoma using single molecule amplification and re-sequencing technology.使用单分子扩增和重测序技术对非小细胞肺癌中的致癌突变进行全面分析和定量。
Oncotarget. 2016 Aug 2;7(31):50477-50489. doi: 10.18632/oncotarget.10464.
8
Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.非小细胞肺癌细胞学样本中间变性淋巴瘤激酶基因重排：与组织学评估的比较。
Cancer Cytopathol. 2014 Jun;122(6):445-53. doi: 10.1002/cncy.21418. Epub 2014 Mar 19.
9
[Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer].[非小细胞肺癌中表皮生长因子受体（EGFR）和间变性淋巴瘤激酶（ALK）基因双突变的研究进展]
Zhongguo Fei Ai Za Zhi. 2018 Sep 20;21(9):686-691. doi: 10.3779/j.issn.1009-3419.2018.09.07.
10
Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).ALK 阳性非小细胞肺癌（NSCLC）患者中初发的 EGFR 或 KRAS 合并突变接受酪氨酸激酶抑制剂（TKI）治疗的临床结局。
J Thorac Oncol. 2017 Apr;12(4):681-688. doi: 10.1016/j.jtho.2016.12.003. Epub 2016 Dec 19.
引用本文的文献
1
Influence of TP53 mutation on efficacy and survival in advanced EGFR-mutant non-small cell lung cancer patients treated with third-generation EGFR tyrosine kinase inhibitors.TP53突变对接受第三代EGFR酪氨酸激酶抑制剂治疗的晚期EGFR突变非小细胞肺癌患者疗效和生存的影响。
MedComm (2020). 2024 Jun 2;5(6):e586. doi: 10.1002/mco2.586. eCollection 2024 Jun.
2
Clinical difference on the variants and co-mutation in a Chinese cohort with ALK-positive advanced non-small cell lung cancer.中国ALK阳性晚期非小细胞肺癌队列中变异和共突变的临床差异
Clin Transl Oncol. 2024 Oct;26(10):2513-2521. doi: 10.1007/s12094-024-03481-w. Epub 2024 Apr 18.
3
Sequential therapy with crizotinib and a second-generation ALK inhibitor versus direct therapy of a second-generation ALK inhibitor in -positive advanced lung cancer: a real-world study.克唑替尼与第二代ALK抑制剂序贯治疗对比第二代ALK抑制剂一线治疗ALK阳性晚期肺癌的真实世界研究
J Thorac Dis. 2023 May 30;15(5):2425-2437. doi: 10.21037/jtd-22-1783. Epub 2023 Apr 7.
4
TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis.TP53 或 CDKN2A/B 共突变与 ALK/RET/ROS1 重排 NSCLC 相关，具有高 TMB、肿瘤免疫抑制微环境和不良预后。
J Cancer Res Clin Oncol. 2023 Sep;149(12):10041-10052. doi: 10.1007/s00432-023-04924-7. Epub 2023 Jun 1.
5
Mutations and expressions of breast cancer 1/2 in lung cancer.乳腺癌 1/2 在肺癌中的突变与表达。
Thorac Cancer. 2023 Jun;14(18):1753-1763. doi: 10.1111/1759-7714.14920. Epub 2023 May 9.
6
Domain-specific p53 mutants activate EGFR by distinct mechanisms exposing tissue-independent therapeutic vulnerabilities.特定领域的 p53 突变体通过不同的机制激活 EGFR，暴露出与组织无关的治疗弱点。
Nat Commun. 2023 Mar 28;14(1):1726. doi: 10.1038/s41467-023-37223-3.
7
Development and validation of a mA -regulated prognostic signature in lung adenocarcinoma.肺腺癌中毫安调节的预后标志物的开发与验证
Front Oncol. 2022 Oct 11;12:947808. doi: 10.3389/fonc.2022.947808. eCollection 2022.
8
Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy.液体活检检测到 ROS1 对 Lorlatinib 治疗的获得性 G2032R 耐药突变。
Curr Oncol. 2022 Sep 16;29(9):6628-6634. doi: 10.3390/curroncol29090520.
9
Metastatic pulmonary carcinoids with fusion response to ALK inhibitors: two case reports and review of literature.对ALK抑制剂有融合反应的转移性肺类癌：两例病例报告及文献综述
Transl Lung Cancer Res. 2022 Jun;11(6):1176-1184. doi: 10.21037/tlcr-22-394.
10
Clinicopathologic characteristics and diagnostic methods of rearrangement in Chinese non-small cell lung cancer patients.中国非小细胞肺癌患者重排的临床病理特征及诊断方法
Transl Lung Cancer Res. 2022 Apr;11(4):617-631. doi: 10.21037/tlcr-22-202.
本文引用的文献
1
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.TP53 突变状态对 ALK 重排非小细胞肺癌系统治疗结局的影响。
Ann Oncol. 2018 Oct 1;29(10):2068-2075. doi: 10.1093/annonc/mdy333.
2
How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.突变如何塑造 p53 与基因组的相互作用，从而促进肿瘤发生和耐药性。
Drug Resist Updat. 2018 May;38:27-43. doi: 10.1016/j.drup.2018.05.001. Epub 2018 May 9.
3
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.一线克唑替尼对比化疗用于 ALK 基因突变阳性非小细胞肺癌的研究的最终总生存分析。
J Clin Oncol. 2018 Aug 1;36(22):2251-2258. doi: 10.1200/JCO.2017.77.4794. Epub 2018 May 16.
4
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound Mutations in ALK-Positive Lung Cancer.序贯 ALK 抑制剂可选择 ALK 阳性肺癌中 lorlatinib 耐药的复合突变。
Cancer Discov. 2018 Jun;8(6):714-729. doi: 10.1158/2159-8290.CD-17-1256. Epub 2018 Apr 12.
5
Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance.与 EGFR 激酶抑制剂耐药相关的 EGFR 突变型肺癌中的伴随改变，以及 MTOR 作为耐药介质的特征。
Clin Cancer Res. 2018 Jul 1;24(13):3108-3118. doi: 10.1158/1078-0432.CCR-17-2961. Epub 2018 Mar 12.
6
Tumor biomarker testing in non-small-cell lung cancer: A decade of change.非小细胞肺癌的肿瘤标志物检测：十年变迁。
Lung Cancer. 2018 Feb;116:90-95. doi: 10.1016/j.lungcan.2018.01.002. Epub 2018 Jan 4.
7
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.美国病理学家学会、国际肺癌研究协会和分子病理学会更新的肺癌患者靶向酪氨酸激酶抑制剂治疗选择的分子检测指南。
J Thorac Oncol. 2018 Mar;13(3):323-358. doi: 10.1016/j.jtho.2017.12.001. Epub 2018 Jan 25.
8
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.EML4-ALK 变异对 ALK 阳性肺癌耐药机制和临床结局的影响。
J Clin Oncol. 2018 Apr 20;36(12):1199-1206. doi: 10.1200/JCO.2017.76.2294. Epub 2018 Jan 26.
9
The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).具有可靶向突变的肺腺癌患者中吸烟和 TP53 突变的影响-肺癌突变联盟（LCMC2）。
Clin Cancer Res. 2018 Mar 1;24(5):1038-1047. doi: 10.1158/1078-0432.CCR-17-2289. Epub 2017 Dec 7.
10
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.劳拉替尼用于治疗具有ALK或ROS1重排的非小细胞肺癌：一项国际多中心、开放标签、单臂首次人体1期试验。
Lancet Oncol. 2017 Dec;18(12):1590-1599. doi: 10.1016/S1470-2045(17)30680-0. Epub 2017 Oct 23.
Zotero 插件